R&D Pipeline

Indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture. As the only bone-forming agent available domestically, it promotes new bone formation, significantly increases bone density, and improves bone quality. The treatment demonstrates a significant reduction in vertebral and non-vertebral fracture risks, interrupts the fracture cascade effect, and lowers the risk of subsequent fractures following an initial osteoporotic fracture.

The Group is advancing its FDA application for Uni-PTH, which has qualified for exemption from bioequivalence testing. This exemption is anticipated to expedite the regulatory approval process, with approval expected as early as 2027. Uni-PTH is projected to become the Group’s first commercialized overseas product.

A novel transdermal drug delivery approach combining the advantages of subcutaneous injection and transdermal administration. This minimally invasive, pain-free format ensures high patient compliance. It enables physical penetration of the stratum corneum barrier, facilitating drug absorption into subcutaneous tissues and systemic circulation. Soluble microneedle products eliminate reuse risks, thereby reducing the potential for cross-contamination.

BMP2 biomedical material UB‑107, a key growth factor in regenerative medicine, recruits and induces mesenchymal stem cells (MSCs) to differentiate into osteogenic lineages. It is widely used clinically in bone defect reconstruction and spinal fusion surgeries.Using the group's proprietary ECO‑KSFA® technology platform, the Group has established a manufacturing process for the BMP2 active pharmaceutical ingredient (API). The product targets multiple orthopedic applications, including critical-sized bone defects, non-union fractures, and interbody spinal fusion.

Developed in collaboration with Great Bay Bio (GBB) and TigerMed Pebble Accelerator, this innovative weight-loss therapeutic aims to transform obesity treatment. The new targeted antibody is strategically designed to address multiple critical challenges, including gastrointestinal side effects, pancreatitis, increased suicide risk, weight rebound after treatment cessation, muscle loss, and frequent dosing requirements. Development efforts are now advancing this breakthrough targeted antibody into clinical trials, accelerating its path to market.

Using the newly operational Blow-Fill-Seal (BFS) production line in Dongguan, next-generation GeneSoft^® products are being developed. These include a 0.5 mL BFS single-dose (daily disposable) format and a 3 mL BFS multi-dose preservative-free format, with submissions to regulatory authorities for supplemental approvals planned for 2026.

UB102, a bispecific nanobody, represents a promising candidate for treating ocular conditions such as wet age-related macular degeneration (wAMD). Preliminary in vitro studies demonstrate significantly higher binding affinity of UB102 toward its targets—vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). This enhanced affinity may translate into improved efficacy and extended dosing intervals, potentially delivering substantial patient benefits.

Indicated for burn wounds, residual small wounds, various chronic ulcers, and fresh skin graft donor sites. The solution promotes cell migration and accelerates the initiation of regeneration, providing a foundation for tissue renewal and repair. It regulates cell growth genes, stimulates DNA and RNA replication along with protein synthesis, modulates collagen metabolism, and enhances extracellular matrix production. These actions collectively reduce scar formation and improve healing quality.

The EGF ( thermosensitive gel ) remains liquid at low temperatures and solidifies at room temperature. Prior to application, the formulation offers excellent flowability, effectively filling wound cavities. Additionally, the gel layer forms a protective barrier between the wound and the external environment, significantly reducing the risk of infection. Formulation development was completed in 2024, with preliminary efficacy tests conducted on deep partial-thickness burn models in rats and Bama pigs. Compared to solution formulations, the thermosensitive gel provides sustained action, effectively maintains moist wound healing, accelerates wound closure, and reduces scar formation.